IDRA-21 vs Semax
A side-by-side research comparison of IDRA-21 and Semax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | IDRA-21 | Semax |
|---|---|---|
| Full name | IDRA-21 (Benzothiadiazide AMPA PAM) | Semax (ACTH 4-10 analog) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Binds AMPA receptors allosterically, reducing desensitization rates to prolong excitatory currents and facilitate LTP for memory encoding. | Activates MC3/4R, increases BDNF and NGF, modulates dopamine/serotonin, enhances neuronal survival via TrkB, and promotes CREB-mediated neuroplasticity. |
| Molecular weight | 262.7 Da | 813.9 Da |
| Half-life | 8-12 hours (effects persist 48-72h) | 3-5 min (systemic) / extended (intranasal) |
| Bioavailability | High (oral) | Moderate (intranasal) |
| Typical dose | 10-30 mg | 200-600 mcg per dose |
| Frequency | 2-3x per week | 2-3x daily |
| Route | Oral | Intranasal drops/spray |
IDRA-21 reported benefits
- AMPA receptor potentiation
- Enhanced memory consolidation
- Improved learning speed
- Long-lasting effects
- Oral bioavailability
Semax reported benefits
- Enhanced attention/focus
- Memory improvement
- Neuroprotection (stroke)
- BDNF/NGF upregulation
- Improved learning
- Optic nerve support
Related comparisons
Research and educational reference only. Not medical advice.